Advertisement

Advertisement

2019 MASCC/ISOO Annual Meeting

Supportive Care
Symptom Management

Virtual Reality May Improve Pain, Vision, Functioning in Patients With Cancer

Virtual reality can be used to improve functioning in patients with cancer, according to David Rhew, MD, Chief Medical Officer, Vice President and General Manager of Enterprise Healthcare, Samsung Ele...

Issues in Oncology
Geriatric Oncology

Polypharmacy Associated With Functional Decline in Older Patients With Advanced Cancer

Polypharmacy (ie, the concurrent use of eight or more medications) and potentially inappropriate medications may be associated with functional impairment in older adults with advanced cancer, accordin...

Issues in Oncology
Pain Management

Opioids for Cancer Pain: A Review of the Evidence and Current Challenges

In the wake of the opioid crisis in the United States, patients with cancer pain are often undeservedly confronted with rigid barriers to receiving the opioids they need. To compound this problem, the...

MASCC’s 2019 Distinguished Service Award Winner

Rachel Gibson, PhD, was named the recipient of MASCC’s 2019 Distinguished Service Award, MASCC’s highest honor. The award is made in recognition of meritorious achievement and outstanding contributio...

Survivorship

Preserving Sexuality and Restoring Sexual Function in Male and Female Cancer Survivors

Intimacy changes after a cancer diagnosis. Both male and female survivors can experience significant sexual dysfunction, pain with sex, loss of desire, and a slew of other clinical and psychological s...

Symptom Management
Supportive Care

Novel Therapeutics on the Horizon for Treating Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy is a major clinical problem, and better therapies are needed for both its treatment and prevention. According to Charles Loprinzi, MD, a medical oncologist a...

Lung Cancer

Studies Find Trilaciclib May Improve Chemotherapy Experience for Patients With Small Cell Lung Cancer

In patients with extensive-stage small cell lung cancer (SCLC), adding trilaciclib to standard-of-care chemotherapy demonstrated meaningful delays in deterioration of myelosuppression-related symptoms...

Advertisement

Advertisement




Advertisement